Amgen's master trial for Hard-to-Treat prostate cancer hits early hurdles
NCT ID NCT04631601
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This master trial tested several drug combinations, including a new targeted therapy called acapatamab, in 65 men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to check safety and early signs of effectiveness. The study was terminated early, so results are limited, but it may provide clues for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Acapatamab (PSMA-targeted therapy), enzalutamide, abiraterone, and AMG 404 (PD-1 inhibitor)
What this could lead to
If successful, this could point toward new treatment options for advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This early-phase trial was terminated, so results are limited. The drugs may cause significant side effects, and it is unclear if they will improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akademiska sjukhuset
Uppsala, 75185, Sweden
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Karolinska Universitetssjukhuset Solna
Stockholm, 171 76, Sweden
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
Rigshospitalet
København Ø, 2100, Denmark
-
Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
Skanes universitetssjukhus
Lund, 221 85, Sweden
-
St Vincents Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California San Francisco Mission Bay Campus
San Francisco, California, 94158, United States
-
University of California at Irvine Medical Center
Orange, California, 92868, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States